Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.
ENTEROME has raised $19.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2025.
ENTEROME's investors include European Investment Bank, Omnes Capital, Seventure Partners, Bristol-Myers Squibb, Primo Capital.
ENTEROME is headquartered in Paris, France.
Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.
ENTEROME is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ENTEROME — Funding & Investors." VCBacked, June 12, 2025, https://www.vcbacked.co/company/enterome. Accessed July 20, 2026.
VCBacked. (2025). ENTEROME — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/enterome
{{cite web |title=ENTEROME — Funding & Investors |url=https://www.vcbacked.co/company/enterome |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated